echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Voriconazole for injection by Puli Pharmaceuticals obtains marketing approval from the Ministry of Health of Costa Rica

    Voriconazole for injection by Puli Pharmaceuticals obtains marketing approval from the Ministry of Health of Costa Rica

    • Last Update: 2021-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 31, Puli Pharmaceuticals issued an announcement stating that the company had recently received a marketing permit for 200 mg of voriconazole for injection issued by the Ministry of Health of Costa Rica


    Voriconazole is a broad-spectrum triazole antifungal agent that treats invasive aspergillosis, candidaemia in patients with non-neutropenia, and severe invasive infections caused by fluconazole-resistant Candida ( Including Candida krusei), a serious infection caused by Actinomyces spp.


    Voriconazole for injection was developed by Pfizer.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.